Skip to main content
Premium Trial:

Request an Annual Quote

DuPont Listeria Assay Gets AOAC Certification

NEW YORK (GenomeWeb News) —DuPont said today that its BAX System real-time PCR assay for Listeria species has been certified by the AOAC Research Institute as a Performance Tested Method.

The assay has been validated on frankfurters, cooked shrimp, spinach, queso fresco, and environmental surfaces using reference method media as well as proprietary media for a shorter, single-stage enrichment, DuPont said.

The AOAC Research Institute, a subsidiary of AOAC International in Rockville, Md., validated the BAX System method as equivalent to the reference culture method for detecting Listeria species, but with much faster time to results, the company added.

BAX System assays for detecting Escherichia coli O157:H7, non-O157 STEC, Campylobacter and other pathogens are already PTM-certified. In addition, AOAC International has awarded Official Method of Analysis status to the system for detecting Salmonella and L. monocytogenes, and DuPont noted that these assays can be run in conjunction with the Listeria species test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.